Active, not recruitingPHASE1, PHASE2NCT05228145
Gene Therapy Study for Children With CLN5 Batten Disease
Studying Batten Disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neurogene Inc.
- Principal Investigator
- Effie Albanis, MD, MDNeurogene Inc.
- Intervention
- NGN-101(genetic)
- Enrollment
- 6 enrolled
- Eligibility
- 3-9 years · All sexes
- Timeline
- 2022 – 2028
Study locations (2)
- University of Rochester, Rochester, New York, United States
- Great Ormond Street Hospital for Children, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05228145 on ClinicalTrials.govOther trials for Batten Disease
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT04273243Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene TransferEmily de los Reyes
- ENROLLING BY INVITATIONNCT03862274Examining Developmental Outcomes of Children Diagnosed With CLN2 DiseaseJessica Scherr
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03770572Gene Therapy for Children With CLN3 Batten DiseaseAlcyone Therapeutics, Inc
- ACTIVE NOT RECRUITINGNCT03285425Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 DiseaeEmily de los Reyes
- RECRUITINGNCT01873924Clinical and Neuropsychological Investigations in Batten DiseaseUniversity of Rochester